Roper Strikes $1.65 Billion Deal to Buy Autism Therapy Software Provider CentralReach

MT Newswires
03-24
Roper ROP.jpg -Shutterstock
Roper Technologies (ROP) said Monday that it agreed to acquire CentralReach, an autism therapy software provider, in a $1.65 billion deal that it expects to close within the next two months.

Roper is buying CentralReach from software investor firm Insight Partners, subject to regulatory approval. The $1.65 billion price tag includes a $200 million tax benefit.

"CentralReach is a fantastic business with clear niche market leadership, mission critical and high (return on investment) solutions, a high recurring revenue mix, and outstanding customer retention, which leads to strong organic revenue growth and excellent cash conversion," Roper Chief Executive Neil Hunn said.

Software and technology company Roper expects about $175 million in revenue contribution and $75 million in earnings before interest, taxes, depreciation, and amortization from CetralReach over a 12-month period ending June 30, 2026. It said CentralReach is anticipated to deliver "sustainable" organic revenue and EBITDA growth of more than 20%.

At the end of January, Roper forecast annual revenue growth of more than 10% for 2025.

In a separate statement, CentralReach said it will continue to operate independently under its current leadership. Its software and services help organizations that serve individuals with autism and intellectual and developmental disabilities.

"With Roper's long-term investment and commitment, CentralReach now has a permanent home where we can continue to scale, innovate, expand our impact, and continue to advance our mission in an even faster and more significant way than we have to date," CentralReach CEO Chris Sullens said.

Insight Partners made a significant investment in CentralReach in 2018. "We are excited to see the company continue its growth and expanding its impact, now with the added strength of Roper," Insight Partners Managing Director Richard Wells said.













免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10